Home Carboxes 22177-92-0
22177-92-0,MFCD00466219
Catalog No.:AA0038SX

22177-92-0 | 4-(6-Chloropyrimidin-4-yl)morpholine

Pack Size
Purity
Availability
Price(USD)
Quantity
  
250mg
98%
in stock  
$33.00   $23.00
- +
1g
98%
in stock  
$92.00   $64.00
- +
5g
98%
in stock  
$246.00   $172.00
- +
25g
98%
in stock  
$1,142.00   $799.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA0038SX
Chemical Name:
4-(6-Chloropyrimidin-4-yl)morpholine
CAS Number:
22177-92-0
Molecular Formula:
C8H10ClN3O
Molecular Weight:
199.6375
MDL Number:
MFCD00466219
SMILES:
Clc1ncnc(c1)N1CCOCC1
Properties
Computed Properties
 
Complexity:
164  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
13  
Hydrogen Bond Acceptor Count:
4  
Rotatable Bond Count:
1  
XLogP3:
1.2  

Downstream Synthesis Route

[1]CurrentPatentAssignee:UNITEDARABEMIRATESUNIVERSITY-US10702525,2020,B1Locationinpatent:Page/Pagecolumn6

[2]CurrentPatentAssignee:NOVARTISAG;Barsanti,PaulA.;Burger,Matthew;Lou,Yan;Nishiguchi,Gisele;Polyakov,Valery;Ramurthy,Savithri;Rico,Alice;Setti,Lina;Smith,Aaron;Taft,Benjamin;Tanner,Huw;DiPesa,Alan;Yusuff,Naeem-US2014/275003,2014,A1Locationinpatent:Paragraph0250;0251

[3]vanderWesthuyzen,ChristiaanW.;Rousseau,AmandaL.;Parkinson,ChristopherJ.[Tetrahedron,2007,vol.63,#25,p.5394-5405]

[4]Borthwick,JenniferA.;Alemparte,Carlos;Wall,Ian;Whitehurst,BenjaminC.;Argyrou,Argyrides;Burley,Glenn;DeDios-Anton,Paco;Guijarro,Laura;Monteiro,MariaCandida;Ortega,Fatima;Suckling,ColinJ;Pichel,JuliaCastro;Cacho,Monica;Young,RobertJ.[JournalofMedicinalChemistry,2020,vol.63,#5,p.2557-2576]

[5]CurrentPatentAssignee:BAYERAG-US2010/305085,2010,A1Locationinpatent:Page/Pagecolumn20

[6]CurrentPatentAssignee:BAYERAG-US2012/264704,2012,A1Locationinpatent:Page/Pagecolumn16

[7]Sengmany,Stéphane;Lebre,Julie;LeGall,Ewan;Léonel,Eric[Tetrahedron,2015,vol.71,#29,p.4859-4867]

[8]Beck,Hartmut;Jeske,Mario;Thede,Kai;Stoll,Friederike;Flamme,Ingo;Akbaba,Metin;Ergüden,Jens-Kerim;Karig,Gunter;Keldenich,Jörg;Oehme,Felix;Militzer,Hans-Christian;Hartung,IngoV.;Thuss,Uwe[ChemMedChem,2018,vol.13,#10,p.988-1003]

[9]Toledo-Sherman,LeticiaM.;Prime,MichaelE.;Mrzljak,Ladislav;Beconi,MariaG.;Beresford,Alan;Brookfield,FrederickA.;Brown,ChristopherJ.;Cardaun,Isabell;Courtney,StephenM.;Dijkman,Ulrike;Hamelin-Flegg,Estelle;Johnson,PeterD.;Kempf,Valerie;Lyons,Kathy;Matthews,Kimberly;Mitchell,WilliamL.;Oconnell,Catherine;Pena,Paula;Powell,Kendall;Rassoulpour,Arash;Reed,Laura;Reindl,Wolfgang;Selvaratnam,Suganathan;Friley,WeslynWard;Weddell,DerekA.;Went,NaomiE.;Wheelan,Patricia;Winkler,Christin;Winkler,Dirk;Wityak,John;Yarnold,ChristopherJ.;Yates,Dawn;Munoz-Sanjuan,Ignacio;Dominguez,Celia[JournalofMedicinalChemistry,2015,vol.58,#3,p.1159-1183]

[10]CurrentPatentAssignee:BIOGENIDECINC.-WO2020/61150,2020,A1Locationinpatent:Paragraph00223

[11]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2017/12576,2017,A1Locationinpatent:Page/Pagecolumn73

[12]Nishiguchi,GiseleA.;Rico,Alice;Tanner,Huw;Aversa,RobertJ.;Taft,BenjaminR.;Subramanian,Sharadha;Setti,Lina;Burger,MatthewT.;Wan,Lifeng;Tamez,Victoriano;Smith,Aaron;Lou,Yan;Barsanti,PaulA.;Appleton,BrentA.;Mamo,Mulugeta;Tandeske,Laura;Dix,Ina;Tellew,JohnE.;Huang,Shenlin;MathewsGriner,LesleyA.;Cooke,VesselinaG.;VanAbbema,Anne;Merritt,Hanne;Ma,Sylvia;Gampa,Kalyani;Feng,Fei;Yuan,Jing;Wang,Yingyun;Haling,JacobR.;Vaziri,Sepideh;Hekmat-Nejad,Mohammad;Jansen,JohannaM.;Polyakov,Valery;Zang,Richard;Sethuraman,Vijay;Amiri,Payman;Singh,Mallika;Lees,Emma;Shao,Wenlin;Stuart,DarrinD.;Dillon,MichaelP.;Ramurthy,Savithri[JournalofMedicinalChemistry,2017,vol.60,#12,p.4869-4881]

[13]CurrentPatentAssignee:EVOTECAG;ESCAPEBIO-WO2019/222173,2019,A1Locationinpatent:Page/Pagecolumn67-69

[14]Locationinpatent:schemeortableJakubkiene,Virginija;Čikotiene,Inga[Tetrahedron,2012,vol.68,#10,p.2294-2298]

[1]Patent:US2010/305085,2010,A1.Locationinpatent:Page/Pagecolumn20

[2]Patent:US2012/264704,2012,A1.Locationinpatent:Page/Pagecolumn16

[3]ChemMedChem,2018,vol.13,p.988-1003

[1]Locationinpatent:experimentalpartSengmany,Stephane;LeGall,Erwan;Leonel,Eric[Molecules,2011,vol.16,#7,p.5550-5560]

22177-92-0   
2-(6-morpholin-4-yl-pyrimidin-4-yl)-4-pyridin-3-yl-1,2-dihydro-3H-pyrazol-3-onehydrochloride 

[1]CurrentPatentAssignee:BAYERAG-US2012/264704,2012,A1

22177-92-0   
4-(5-bromopyridin-3-yl)-2-(6-morpholin-4-ylpyrimidin-4-yl)-1,2-dihydro-3H-pyrazol-3-onehydrochloride 

[1]CurrentPatentAssignee:BAYERAG-US2012/264704,2012,A1

Literature

Title: Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

Journal: Bioorganic & medicinal chemistry letters 20101101

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:22177-92-0 Molecular Formula|22177-92-0 MDL|22177-92-0 SMILES|22177-92-0 4-(6-Chloropyrimidin-4-yl)morpholine